相关临床试验
7
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1946
已完成
6
85.7%
尚未招募
1
14.3%
暂无批准数据
- A global mpox vaccine stockpile launched on 27 August 2025, funded by Gavi and coordinated by the International Coordinating Group (ICG) on Vaccine Provision, will begin operations later this month. - The initiative builds on the 2024 Access and Allocation Mechanism to ensure countries access vaccines based on need rather than ability to pay, addressing inequities exposed during the 2022 outbreak. - From 1 January 2022 to 31 July 2026, 145 countries and territories reported 190,683 confirmed mpox cases and 529 deaths, with about two-thirds of cases occurring in the African Region. - Partners including IFRC, MSF, UNICEF, and WHO emphasized that the stockpile will help vaccines reach children, families, and communities at greatest risk more quickly.
- FSSAI has told the Supreme Court it proposes a red hexagonal front-of-pack warning label for foods high in added saturated fat, added sugar and salt. - The regulator proposes a phased rollout, with Phase I covering products high in two or more nutrients of concern and specified sweetened beverages. - The Supreme Court flagged unresolved issues on thresholds, phasing timelines, label design, font size and placement, and directed FSSAI to file a further affidavit within ten days. - The next hearing is scheduled for 28.09.2026 in the petition brought by public charitable trust 3S and Our Health Society.
- Moldova received 50,310 doses of the Pfizer-BioNTech mRNA COVID-19 vaccine on May 20, 2021, delivered free through the COVAX platform. - An additional 50,310 Pfizer-BioNTech doses are scheduled for delivery on May 21, bringing the total to 100,620 doses, with 45,600 AstraZeneca doses to follow on May 24. - The Pfizer-BioNTech vaccine has demonstrated 92% efficacy against SARS-CoV-2 infection and 94% efficacy against symptomatic COVID-19 in clinical studies. - Moldova was the first European country to receive COVID-19 vaccine doses through the COVAX platform, which aims to ensure equitable global vaccine access.
- In 2025, 90% of infants globally received at least one DTP dose, yet coverage remains one point below 2019 levels and has stagnated within a narrow range since 2009. - An estimated 13.5 million "zero-dose" children received no vaccines in their first year, with over half living in fragile, conflict-affected settings. - Measles coverage stalled at 84% for the first dose, far below the 95% threshold needed to prevent outbreaks, with 57 countries reporting large or disruptive measles outbreaks in 2025. - WHO and UNICEF warn that cuts to international health financing and declining immunization surveys threaten progress toward the Immunization Agenda 2030 targets.
- Cuba's once-vaunted free universal healthcare system is deteriorating sharply due to fuel shortages and power outages lasting over 20 hours, compounded by tightened U.S. sanctions on the energy sector. - The survival rate for children with cancer has fallen to 65% from 85% since energy restrictions began in January, with two pediatric deaths reported so far this year. - Approximately 100,000 Cubans are on surgery waiting lists, nearly 3,000 kidney dialysis patients face disrupted treatment schedules, and 300 of 395 essential medicines are unavailable. - The United Nations launched a $94 million emergency plan in March, but humanitarian agencies report significant logistical challenges in delivering antibiotics, reagents, and food aid.
- As of the latest reports, over 340 confirmed Ebola cases and 60 deaths have been recorded across more than 20 health zones in the DRC, with the outbreak crossing into neighboring Uganda. - Frontline doctors describe an environment "marked by fear, urgency, uncertainty," where community distrust and misinformation lead patients to delay seeking care and resist isolation measures. - Active armed conflict and population displacement in the Ituri region severely limit contact tracing, with the International Rescue Committee noting only about 20% of contacts are currently being traced. - Health officials report that treatment centers were overwhelmed, forcing some suspected cases to be turned away, though international aid has since mobilized to scale up response efforts.
- ETVAX demonstrated up to 80.6% effectiveness against enterotoxigenic E. coli (ETEC) diarrhea in children without intestinal parasites, marking the first oral ETEC vaccine to show real protection in high-burden settings. - The Phase IIb trial in Gambia enrolled 4,936 children aged 6-18 months and found 67.8% protection in infants who started vaccination before nine months of age. - While missing its primary endpoint with 26.6% efficacy, ETVAX showed 48.2% effectiveness against ETEC regardless of co-infections and reduced all-cause moderate-to-severe diarrhea by 21%. - The European Medicines Agency has approved progression to a pivotal Phase III trial with 5,800 infants, potentially leading to the first approved vaccine against ETEC infections that cause 42,000 annual deaths.
- Merck has formalized a technology transfer agreement with Universal Corporation Limited to establish local production of arpraziquantel, a pediatric formulation for treating schistosomiasis in children aged three months to six years. - The partnership aims to position Kenya as a regional pharmaceutical leader, with production expected to supply Sub-Saharan Africa from 2028 onwards, reducing dependence on donor supply chains. - Schistosomiasis affects more than 250 million people globally with Africa carrying the heaviest burden, and Kenya has 17 of the 21 WHO-listed neglected tropical diseases. - The initiative represents a significant step toward African pharmaceutical self-sufficiency, combining knowledge transfer, technical expertise, and sustainable access models for neglected tropical disease treatment.
- The World Health Organization has prequalified Pfizer's Abrysvo as the first maternal RSV vaccine, enabling procurement by international agencies for low- and lower-middle-income countries. - WHO published its first position paper recommending two RSV immunization products: maternal vaccine RSVpreF and monoclonal antibody nirsevimab to protect infants from severe disease. - RSV causes an estimated 100,000 deaths and over 3.6 million hospitalizations annually in children under five, with 97% of fatalities occurring in low- and middle-income countries. - The maternal vaccine is recommended from 28 weeks of gestation onwards, while nirsevimab is administered as a single dose to infants at birth or before hospital discharge.
- Ocean Biomedical's research team, led by Dr. Jonathan Kurtis, has received $3.5 million in NIH funding to advance their innovative malaria vaccine research targeting the GARP protein. - The company is developing three vaccine candidates currently in non-human primate trials, supported by a $4.6 million foundation grant, with potential human trials starting in Q4 2025. - New FDA guidance on lipid-encapsulated vaccines may accelerate the development pathway for Ocean Biomedical's malaria vaccine, which targets a disease that claims over 500,000 children's lives annually in sub-Saharan Africa.
